353 related articles for article (PubMed ID: 26435210)
1. Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.
Angata T; Nycholat CM; Macauley MS
Trends Pharmacol Sci; 2015 Oct; 36(10):645-660. PubMed ID: 26435210
[TBL] [Abstract][Full Text] [Related]
2. Siglecs as targets for therapy in immune-cell-mediated disease.
O'Reilly MK; Paulson JC
Trends Pharmacol Sci; 2009 May; 30(5):240-8. PubMed ID: 19359050
[TBL] [Abstract][Full Text] [Related]
3. Current Status on Therapeutic Molecules Targeting Siglec Receptors.
Lenza MP; Atxabal U; Oyenarte I; Jiménez-Barbero J; Ereño-Orbea J
Cells; 2020 Dec; 9(12):. PubMed ID: 33333862
[TBL] [Abstract][Full Text] [Related]
4. Siglec and anti-Siglec therapies.
Murugesan G; Weigle B; Crocker PR
Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
[TBL] [Abstract][Full Text] [Related]
5. B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.
Meyer SJ; Linder AT; Brandl C; Nitschke L
Front Immunol; 2018; 9():2820. PubMed ID: 30559744
[TBL] [Abstract][Full Text] [Related]
6. Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses.
Läubli H; Varki A
Cell Mol Life Sci; 2020 Feb; 77(4):593-605. PubMed ID: 31485715
[TBL] [Abstract][Full Text] [Related]
7. Targeting siglecs--a novel pharmacological strategy for immuno- and glycotherapy.
Jandus C; Simon HU; von Gunten S
Biochem Pharmacol; 2011 Aug; 82(4):323-32. PubMed ID: 21658374
[TBL] [Abstract][Full Text] [Related]
8. Structural advances of Siglecs: insight into synthetic glycan ligands for immunomodulation.
Movsisyan LD; Macauley MS
Org Biomol Chem; 2020 Aug; 18(30):5784-5797. PubMed ID: 32756649
[TBL] [Abstract][Full Text] [Related]
9. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
10. Impact of Siglecs on autoimmune diseases.
Brzezicka KA; Paulson JC
Mol Aspects Med; 2023 Apr; 90():101140. PubMed ID: 36055802
[TBL] [Abstract][Full Text] [Related]
11. A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands.
Rodrigues E; Jung J; Park H; Loo C; Soukhtehzari S; Kitova EN; Mozaneh F; Daskhan G; Schmidt EN; Aghanya V; Sarkar S; Streith L; St Laurent CD; Nguyen L; Julien JP; West LJ; Williams KC; Klassen JS; Macauley MS
Nat Commun; 2020 Oct; 11(1):5091. PubMed ID: 33037195
[TBL] [Abstract][Full Text] [Related]
12. Advances in understanding and exploiting Siglec-glycan interactions.
Jame-Chenarboo Z; Gray TE; Macauley MS
Curr Opin Chem Biol; 2024 Apr; 80():102454. PubMed ID: 38631213
[TBL] [Abstract][Full Text] [Related]
13. Flow Cytometry-Based Detection of Siglec Ligands.
Schmidt EN; Jung J; Macauley MS
Methods Mol Biol; 2023; 2657():181-193. PubMed ID: 37149531
[TBL] [Abstract][Full Text] [Related]
14. Preparation of Recombinant Siglecs and Identification of Their Ligands.
Chang LY; Low PY; Sridharan D; Gerlovin K; Angata T
Methods Mol Biol; 2020; 2132():85-98. PubMed ID: 32306317
[TBL] [Abstract][Full Text] [Related]
15. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions.
Lübbers J; Rodríguez E; van Kooyk Y
Front Immunol; 2018; 9():2807. PubMed ID: 30581432
[TBL] [Abstract][Full Text] [Related]
17. Murine Red Blood Cells Lack Ligands for B Cell Siglecs, Allowing Strong Activation by Erythrocyte Surface Antigens.
Spiller F; Nycholat CM; Kikuchi C; Paulson JC; Macauley MS
J Immunol; 2018 Feb; 200(3):949-956. PubMed ID: 29288201
[TBL] [Abstract][Full Text] [Related]
18. High-affinity ligands of Siglec receptors and their therapeutic potentials.
Magesh S; Ando H; Tsubata T; Ishida H; Kiso M
Curr Med Chem; 2011; 18(23):3537-50. PubMed ID: 21756229
[TBL] [Abstract][Full Text] [Related]
19. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
20. Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22.
Chen WC; Sigal DS; Saven A; Paulson JC
Leuk Lymphoma; 2012 Feb; 53(2):208-10. PubMed ID: 21756025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
